What the trial was testing
The NAPOLI 3 enrolled 770 patients with pancreatic cancer. The study was sponsored by Ipsen and tracked outcomes across the full group of patients who matched the trial's eligibility profile.
It was a large trial designed to confirm whether the treatment works well enough for wider use. Trials at this stage are designed to produce evidence regulators and physicians can act on — not just observations to follow up later.
What the results showed
People who got NALIRIFOX lived 11.1 months on average, compared to 9.2 months with standard treatment.
Lancet (London, England) · 2023 · NCT04083235
These findings — that people lived nearly two months longer with NALIRIFOX than standard treatment — were published in the Lancet (London, England) and represent the headline result of the study.
Researchers tracked outcomes across 770 patients enrolled in the trial. The result was consistent enough across the group that the team felt confident reporting it.
What this means for patients
For patients with pancreatic cancer, this result changes the calculus on what to ask their care team about. Whether it changes day-to-day care depends on factors like disease subtype, prior treatments, and where the patient is in their care journey.
What you can do now
NALIRIFOX is FDA-approved for metastatic pancreatic cancer. It combines four drugs given through an IV every two weeks. The trial showed it helped people live longer than another common treatment. Talk to your oncologist about whether NALIRIFOX is right for your situation.
Eligibility for the treatments mentioned above depends on specific test results and clinical history. Bring this summary, the trial name, and your most recent labs or pathology report to your next visit.
Open pancreatic cancer trials
Exploring the Impact of a Multi-modal Nutritional Intervention in Patients Undergoing Chemotherapy for Pancreatic Cancer (FEED Trial)
The study will examine if a multi-modal nutritional care package, with or without resistance training delivered with neoadjuvant chemotherapy, is effective at preventing loss of muscle strength during neoadjuvant chemotherapy for pancreatic cancer. There are two arms in this study: Control Arm will receive standard dietetic care and be prescribed standard pancreatic enzyme replacement therapy and oral nutritional supplement drinks with their neoadjuvant chemotherapy. The intervention Arm will have 3 additional dietitian visits and 6 physiotherapist visits that the control group will not.
Multicentric Database for Solid Pseudopapillary Neoplasm of the Pancreas
To establish and maintain a reliable multicenter real-world database for pancreatic SPN, providing high-quality data and evidence-based support for clinical/translational research.